Market News
Smart Trading. Simplified.
A stock that yields 67% a year? Really?
In today's helter-skelter market, most investors would be happy with stocks yielding 4% or 5%. But they'd be setting their sights too low. Because I've built a portfolio that pays us a 67% cash on cash return - with no leverage, options, or gimmicks.
Sponsored
Is Tootsie Roll Stock A Buy?
Tootsie Roll Industries, Inc. (NYSE:TR) is a company you may not have even realized was public. But it found itself in the Reddit spotlight when the WallStreetBets community targeted it for a short squeeze. This briefly shot TR share price up to the moon – to a high of $57.26 – before falling back to […]
Elon Musk Drops MASSIVE Bombshell
The shrewd billionaire just made a VERY strange confession about the future of his electric car empire. The secret he reveals could also mint fortunes for smart, fast-moving investors. This has nothing to do with buying shares of Tesla.
Click here for the stunning details.
Sponsored
Amazon Investment Thesis
Very few companies can say that they have surpassed the $1 trillion mark, but Amazon is solidly on that list. With a current valuation of more than $1.5 trillion, some suggest it could hit $2 trillion over the next year. However, some detractors insist the recent rise was driven by COVID-19 alone, and share prices […]
Stock Market Whiz Kid Works 1 Hour a Day. Makes Millions.
He was living with his parents. Two years later he had $5 million to play with - all because of this 1 EXTRA INCOME strategy.
To see how he did it click here.
Sponsored
Is Baidu Stock A Good Buy?
Is Baidu Stock A Good Buy? The stock markets are more volatile than a teenager having a temper tantrum right now. The never-ending pandemic, another possible recession, and the GameStop controversy have seen stocks drop and pop and drop again. You’d think investing in tech stocks — during a year when everyone’s at home using tech […]
Small Biotech Firm Stuns World
On November 16, 2016 a small biotech used a radical new treatment to restore blindness in mice. CBS News called this breakthrough "the most consequential discovery in biomedicine this century."
Investors who get in early are set to earn 46,751% returns.
Sponsored
Is Novavax Stock A Buy?
Novavax, Inc. (NASDAQ:NVAX) is an American biotech company that’s late in the vaccine race, but it may have a winning horse. The company announced an agreement to presell 1.1 million doses of its coronavirus vaccine to COVAX, an organization that includes several prominent health organizations. With the details somewhat hazy right now, is Novavax stock […]
Man Gets Into a Tesla... What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown... I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project...
What happens next will shock you..."
Click here to see what happened.
Sponsored
Is Sundial Growers Stock A Buy?
Sundial Growers Inc (NASDAQ:SNDL) took center stage on Reddit’s WallStreetBets community for a brief period in February. This pushed its share prices up to a high of $3.96, a level it hasn’t reached for some time. The spark behind the rally was due to cannabis sales continuing to surge through the widespread shutdowns. For investors […]
Tiny Massachusetts Company Awarded $75 Billion Patent
Tiny biotech's breakthrough proves it's possible to remove cancer cells from sick patients. Bill Gates says new discovery is so powerful it could "help humanity." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $1.57 Million >>>
Sponsored
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment